

04-17-06

Jfw

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97 (c))

Docket No.

319/04326

In Re Application of:

Dror OFER

Application No.	Filing Date	Examiner	Customer No.	Art Unit	Confirmation No.
10/523,131	January 21, 2005	UNKNOWN	44909	1645	1264

Title:

DRUG DISCOVERY METHOD

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).



TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97 (c))

Docket No.

319/04326

In Re Application of::

Dror OFER

Application No.	Filing Date	Examiner	Customer No.	Art Unit	Confirmation No.
10/523,131	January 21, 2005	UNKNOWN	44909	1645	1264

Title:

DRUG DISCOVERY METHOD

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 03-3419 as described below.
- ☐ Charge the amount of \$00.00
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date) _____

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail


I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____

(Date) _____

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Signing Certificate


*This certificate may only be used if paying by deposit account.



Maier Fenster, Reg. No. 41,016

William H. Dippert, Esq.
Wolf, Block, Schorr & Solis-Cohen LLP
250 Park Avenue
New York, New York 10177
Tel: (212) 986 1116

¹⁰
Date: April 7, 2006



TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97 (c))

Docket No.

319/04326

In Re Application of::

Dror OFER

Application No.	Filing Date	Examiner	Customer No.	Art Unit	Confirmation No.
10/523,131	January 21, 2005	UNKNOWN	44909	1645	1264

Title:

DRUG DISCOVERY METHOD

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 03-3419 as described below.
- ☐ Charge the amount of \$00.00
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date) _____

Signature _____

Typed or Printed Name of Person Signing Certificate _____

Certificate of Mailing by First Class Mail


I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____

(Date) _____

Signature of Person Mailing Correspondence _____


Typed or Printed Name of Person Signing Certificate _____

*This certificate may only be used if paying by deposit account.


Maier Fenster, Reg. No. 41,016

Date: April 7, 2006

William H. Dippert, Esq.
Wolf, Block, Schorr & Solis-Cohen LLP
250 Park Avenue
New York, New York 10177
Tel: (212) 986 1116



PTO/SB92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Express Mail Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service Express Mail under 37 CFR 1.10 on the date indicated below and is addressed to:

Mail Stop: AMENDMENT
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on April 13, 2006

Date

EV793701299US

Express Mail Label

Geraldine Gress

Wolf, Block, Schorr and Solis-Cohen LLP
250 Park Avenue
10th Floor
New York, New York 10177-0030
Telephone: 212.986.1116; Facsimile: 212.986.0604

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Applicant: Dror Ofer
Serial No: 10/523,131
Filing Date: January 21, 2005
For: Drug Discovery Method
Enclosures: (1) Transmittal of Information Disclosure Statement (3 pages);
(2) Information Disclosure Statement (2 pages);
(3) IDS Citation (7 pages) w/cited references;
(4) Acknowledgement Postcard

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



319/04326

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In regard to the application of: Dror OFER

Serial No : 10/523,131

Group Art Unit: 1645

Filed : January 21, 2005

Examiner: Unknown

For : DRUG DISCOVERY-METHOD

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants respectfully direct the attention of the Examiner to art cited with respect to U.S. Application No. 10/523,131, which is a US National Phase of PCT/IL02/00614.

The Examiner is respectfully requested to review and consider this art, in accordance with MPEP §2001.06 and to indicate in the first office action that he has considered this art. Additionally, the Examiner is respectfully requested to cite those prior art publications mentioned in this application which the Examiner considers to be material or relevant to the present claims.

Further, in order to comply with discretionary regulations 37 C.F.R. §1.97 and §1.98, attached is an Equivalent to Form PTO-1449 listing the cited art. Also attached are copies¹ of the art. This art contains information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

Copies of items 1 - 2 are not attached, as the USPTO waived the requirement under 37 CFR 1.98(a)(2)(i) for submitting copies of US patents and US patent application publications in all U.S. applications filed after June 30, 2003. See MPEP 609 III A(2).

In accordance with MPEP §609 it is requested that each document cited (including any mentioned in Applicants' specification which is not repeated on the attached PTO-1449 form(s) or equivalents thereof) be given thorough consideration and be cited of record in the


¹ To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the national stage file. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached, it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such an equivalent patent is also cited on the attached form along with the corresponding foreign language

prosecution history of the present application by initialing on the PTO-1449 form or its equivalent, so that it will appear on the face of the patent issuing on the present application, even if the Examiner does not consider it sufficiently pertinent to use in a rejection, or otherwise does not believe that the guidelines for citation have been fully complied with.

The present Information Disclosure Statement is being submitted in compliance with 37 C.F.R. §1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 C.F.R. §1.104(a), and in the course of such search will review for relevance every document cited on the attached form.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,
Dror OFER




Maier FENSTER
Registration No. 41,016

April 2, 2006

William H. Dippert, Esq.
Wolf, Block, Schorr & Solis-Cohen LLP
250 Park Avenue
New York, NY 10177

Tel: 212-986-1116



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY DOCKET NO. 319/04326	SERIAL NO. 10/523,131
	APPLICANT(S) Dror OFER	
	FILING January 21, 2005	GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	Filing date if appropriate
	1.	6,143,776	07 Nov '00	ERLANSON			
	2.	6,335,155	01 Jan '02	WELLS et al.			

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	Filing date if appropriate

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	3.	EP 1 252 141	02 Feb '01	EUROPE				
	4.	WO 00/00823	06 Jan '00	PCT				
	5.	WO 00/39585	06 Jul '00	PCT				
	6.	WO 01/56987	09 Aug '01	PCT				
	7.	WO 01/98245	27 Dec '01	PCT				
	8.	WO 02/42773	30 May '02	PCT				
	9.	WO 02/44128	06 Jun '02	PCT				
	10.	WO 98/16835	23 Apr '98	PCT				
	11.	WO 99/49314	30 Sep '99	PCT				

OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

	12.	FEJZO et al. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chemistry & Biology, October 1999, Vol. 6, No. 10, Pages 755-769.
	13.	SANNES-LOWERY et al. High-performance mass spectrometry as a drug discovery tool: a high-throughput screening assay to identify RNA-binding ligands. Proceedings of SPIE-The international society for optical engineering (2001), Vol. 4264, pages 27-36.
	14.	DARVAS, F. et al. A Photoactivatable Library Approach for target identification and validation. Publisher: American Chemical Society, Washington, D.C., April 2002.
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Form PTO-A820

(Also form PTO-1449)

Patent and Trademark Office*U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY DOCKET NO. 319/04326	SERIAL NO. 10/523,131
	APPLICANT(S) Dror OFER	
	FILING January 21, 2005	GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	Filing date if appropriate

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLA SS	SUB- CLASS	Filing date if appropriate

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

	15.	"Combinatorial Target-Guided Ligand Assembly: Identification of Potent Subtype-Selective C-Src Inhibitors"; MALY, D.J et al., PNAS; Vol 97; No.6, p.2419-2424; 14 March 2000.
	16.	"Design of Adenosine Kinase Inhibitors from the NMR-Based Screening of Fragments"; HAJDUK, P.J. et al, J.Med. Chem, Vol 43; No. 25, p.4781-4786; 2000.
	17.	"The Combinatorial Synthesis and Chemical and Biological Evaluation of a 1, 4-Benzodiazepine Library"; BUNIN, B.A. et al, Proc. Natl. Acad. Sci USA; Vol. 91, p.4708-4712; May 1994.
	18.	"Site Directed Ligand Discovery"; ERLANSON, D.A. et al, PNAS; Vol. 6, No. 10, p.755-769; October 1999.

EXAMINER	DATE CONSIDERED
-----------------	------------------------

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY DOCKET NO. 319/04326	SERIAL NO. 10/523,131
	APPLICANT(S) Dror OFER	
	FILING January 21, 2005	GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	Filing date if appropriate

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLA SS	SUB- CLASS	Filing date if appropriate

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

	19.	"Combinatorial Thinking in Chemistry and Biology"; ELLMAN J. et al, Proc. Natl. Acad. Sci USA; Vol. 94, p. 2779-2782; April 1997.
	20.	"Designing Chemical Libraries for Lead Discovery"; FERGUSON, A.M. et al, Journal of Biomolecular Screening; 1 (2), p. 65, 1996.
	21.	"Partition-Based Selection"; MASON J.S. et al, Perspectives in Drug Discovery and Designs; 7/8, p. 85-114, 1997.
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Form PTO-A820

Patent and Trademark Office*U.S. DEPARTMENT OF COMMERCE

(Also form PTO-1449)

PAGE 3 OF 7

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY DOCKET NO. 319/04326	SERIAL NO. 10/523,131
	APPLICANT(S) Dror OFER	
	FILING January 21, 2005	GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	Filing date if appropriate

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLA SS	SUB- CLASS	Filing date if appropriate

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

	22.	"Molecular Diversity, Biological Activity and Common ground Shared by both"; CFFEN, D.L. et al, Medical Chemistry Research; 8:4/8, p. 206-218, 1998.
	23.	"The Generation of Carbohydrate-Based Combinatorial Libraries for Drug Discovery"; SOFIA, M.J.; Medical Chemistry Research; 8:7/8; p. 362-378, 1998.
	24.	"DIVSEL and COMPLIB- Strategies for the design and comparison of combinatorial Libraries Using Pharmacophoric Descriptors"; PICKETT, S.D. et al, J. Chem. Inf. Comput. Sci.; 38, p. 144-150, 1998.
	25.	"Diversity Profiling and Design Using 3D Pharmacophores: Pharmacophores-Derived Queries (PDQ)"; PICKETT, S.D. et al, J. Chem. Inf. Comput. Sci.; p.1214-1223, 1996.
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Form PTO-A820

(Also form PTO-1449)

Patent and Trademark Office*U.S. DEPARTMENT OF COMMERCE

PAGE 4 OF 7

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY DOCKET NO. 319/04326	SERIAL NO. 10/523,131
	APPLICANT(S) Dror OFER	
	FILING January 21, 2005	GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	Filing date if appropriate

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	Filing date if appropriate

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

	26.	"Using Pharmacophore Diversity to Select Molecules to Test from Commercial Catalogues"; DAVIES, K.; American Chemical Society; Chap. 27: 309-316.
	27.	"The LDS Advantage: Chemistry, Benefits of Large, Diverse Libraries"; www.pcop.com/discovery/disc-ids/ids_big_libs.html ; downloaded on 25 September 2000; 1 page.
	28.	"The LDS Advantage: Chemistry, Benefits of Early Library Design"; www.pcop.com/discovery/disc-ids/ids_benefits-design.html ; downloaded on 25 September 2000; 1 page.
	29.	"The LDS Advantage: Chemistry, The LDS Collection"; www.pcop.com/discovery/disc-ids/ids_collection.html ; downloaded on 25 September 2000; 1 page.
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Form PTO-A820

Patent and Trademark Office*U.S. DEPARTMENT OF COMMERCE

(Also form PTO-1449)

PAGE 5 OF 7

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY DOCKET NO. 319/04326	SERIAL NO. 10/523,131
	APPLICANT(S) Dror OFER	
	FILING January 21, 2005	GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	Filing date if appropriate

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLA SS	SUB- CLASS	Filing date if appropriate

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

	30.	"The LDS Advantage: Biology, SAR from Primary Screening"; www.pcop.com/discovery/disc-ids/ids_screening4sar.html; downloaded on 25 September 2000; 1 page.
	31.	"The LDS Advantage: Biology, Efficient High Throughput Screening"; www.pcop.com/discovery/disc-ids/ids_effhts.html; downloaded on 25 September 2000; 1 page.
	32.	BORMAN, S.; Special Report: "Recent Concepts and Advances in this Dynamic Field Involve Combinatorial Animals, Target-Guided Ligand Assembly, Fluorous Mixtures, Microencapsulation and Nanoelectrospray Technology"; Vol. 78, No. 20; p. 53-65; 14 pages downloaded from www.cen.acs.org/subscribe/journals on 25 September 2000
	33.	"Library Design and Virtual Screening Using Multiple 4-Point Pharmacophore Fingerprints"; MASON, J.S. et al.
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Form PTO-A820

(Also form PTO-1449)

Patent and Trademark Office*U.S. DEPARTMENT OF COMMERCE

PAGE 6 OF 7

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY DOCKET NO. 319/04326	SERIAL NO. 10/523,131
	APPLICANT(S) Dror OFER	
	FILING January 21, 2005	GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	Filing date if appropriate

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLA SS	SUB- CLASS	Filing date if appropriate

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

	34.	"Network Science: Combinatorial Chemistry Library Design using Pharmacophore Diversity"; DAVIAS K. et al.; www.netsci.org/Science/Combichem/feature05.html ; 6 pages downloaded on 25 September 2000
	35.	"Chem-X Offers Innovative Software Solutions for Compound Discovery"; www.oxmol.com/chemdesign/products.html ; downloaded on 23 November 1998.

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-A820

(Also form PTO-1449)

Patent and Trademark Office*U.S. DEPARTMENT OF COMMERCE

PAGE 7 OF 7